Marty Culjat, PhD is the SVP, Global Head of Digital Medicine & Regulatory Innovation at EVERSANA. In this role, he leads a cross-functional team supporting the commercialization of digital medicine products within companies ranging from startups to large pharma. He is widely recognized as an expert in regulatory affairs and strategy in digital health, having supported more than 50 companies in this area over the past few years, serving as the de-facto regulatory head of digital health within multiple large pharma companies, and serving as a thought leader at various international conferences at the intersection of digital health and pharma. Prior to EVERSANA, he held various executive roles within the emerging digital medicine sector, including: Dthera Sciences, a pioneering digital therapeutics company targeting Alzheimer’s disease; Mymee, a personalized medicine company focused on autoimmune disease; and CureMatch, a precision oncology company using AI and genomics to optimize cancer treatment. Dr. Culjat has a PhD in Biomedical Engineering from UCLA and BS in Bioengineering from UC San Diego.